A unified strategy in selection of the best allometric scaling methods to predict human clearance based on drug disposition pathway. (1st December 2016)

• Record Type: Journal Article
• Authors: Liu, Dongyang; Song, Hanlin; Song, Ling; Liu, Yang; Cao, Yanguang; Jiang, Ji; Hu, Pei
• Is Part Of: Xenobiotica. Volume 46:Number 12(2016:Dec.)
• Page Start: 1105
• Page End: 1111
• Publication Date: 2016-12-01
• Subjects: Allometric scaling -- disposition pathway -- human clearance -- prediction; Metabolism -- Periodicals; Drugs -- Physiological effect -- Periodicals; Food additives -- Periodicals; Chemicals -- Physiological effect -- Periodicals; Biochemistry -- Periodicals; Pharmaceutical Preparations -- metabolism -- Periodicals; Metabolism -- Periodicals; 574.133
• DOI: 10.1080/00498254.2016.1205761
• Languages: English
• ISSNs: 0049-8254

Abstract

Abstract: 1. It is critical to develop a unified strategy to select the best allometric scaling (AS) method for a given group of drugs. 2. A total of 446 drugs with known human CLiv, clear disposition pathway and animal (rat, dog, monkey) CLiv were analyzed. All drugs were stratified based on their disposition pathway, liver extraction ratio ( ERH ) and ratios of unbound clearance to renal glomerular filtration rate ( RGFR ). Up to 22 AS methods were applied and compared in prediction of human CLiv to each group of drugs. 3. AS methods that give the best prediction of human CLiv, were identified for drugs primarily eliminated through liver with a fraction of renal elimination ( frenal ) within 0.3–0.5 or ERH > 0.3, where human CLiv of more than 80% or 90% drugs could be accurately (within 2- or 3-fold error) predicted. For drugs with ERH < 0.3, acceptable accuracy could be achieved by a two species method TSR, D resulting more than 60% or 75% drugs were predicted within 2- or 3-fold error. 4. By stratified analysis of drugs, according to their disposition pathway and organ extraction ratio, a unified strategy was developed to select the best AS method in prediction of human CLiv .